ProKidney Corp Change In Cash Over Time
| PROK Stock | USD 0.97 0.01 1.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProKidney Corp Performance and ProKidney Corp Correlation. ProKidney |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare ProKidney Corp and related stocks such as Relay Therapeutics, Stoke Therapeutics, and Pliant Therapeutics Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLAY | 349.2 M | 349.2 M | 349.2 M | 349.2 M | 349.2 M | 349.2 M | 349.2 M | 349.2 M | 349.2 M | (379.6 M) | 405.7 M | (165.8 M) | (128.3 M) | (7.9 M) | (20 M) | (19 M) |
| STOK | 477 K | 477 K | 477 K | 477 K | 477 K | 477 K | 477 K | 477 K | 103.8 M | 117.1 M | 64.8 M | (142 M) | (31.3 M) | 77.9 M | 70.1 M | 73.6 M |
| PLRX | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 56.7 M | 24.9 M | (34.9 M) | 783 K | (18 M) | 31 M | 8 M | 7 M |
| BDTX | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 43.8 M | 103.1 M | (118.9 M) | 31.2 M | (31.5 M) | 21.6 M | (19.8 M) | (18.8 M) |
| ARVN | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | 25.8 M | (27.7 M) | 6 M | 579.2 M | (475.6 M) | (26 M) | 230.4 M | (216.7 M) | (205.9 M) |
| ACLX | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 20 M | 12.1 M | (15.8 M) | 35.6 M | 332.2 M | (290.6 M) | (276.1 M) |
| VTYX | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (65 K) | 70.5 M | (6 M) | (12.3 M) | (24.3 M) | (23.1 M) |
| IMCR | (51.5 M) | (51.5 M) | (51.5 M) | (51.5 M) | (51.5 M) | (51.5 M) | (51.5 M) | (51.5 M) | 41.5 M | (50.4 M) | 55.8 M | 146 M | 114.3 M | 40.2 M | 13.1 M | 12.4 M |
| PCVX | 27.8 K | 27.8 K | 27.8 K | 27.8 K | 27.8 K | 27.8 K | 27.8 K | 27.8 K | 30 M | (7.1 M) | 327.2 M | (316.3 M) | 765.7 M | (437 M) | (9.4 M) | (8.9 M) |
| THRD | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 120 M | 161 M | (19.8 M) | (17.8 M) | (16.9 M) |
| PMVP | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 43 M | 288.1 M | (188.1 M) | (64.2 M) | (70.6 M) | 2.3 M | 2 M |
| EWTX | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 81.3 M | (89.3 M) | 6.4 M | 64.1 M | (44.4 M) | (42.2 M) |
| RVMD | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | 60.7 M | (52.9 M) | 88.5 M | 4.9 M | 52.9 M | 536 M | (152.4 M) | (144.8 M) |
| KURA | (31.8 K) | 15.8 K | (22.7 K) | 582 | 1.1 M | 14.3 M | (5.7 M) | 1.7 M | 4.7 M | 10 M | 299.6 M | (234.8 M) | (38.9 M) | (14.5 M) | 187.1 M | 196.5 M |
| PTGX | 864 K | 864 K | 864 K | 864 K | 864 K | (5.3 M) | 17 M | 85.4 M | (23.8 M) | (49.2 M) | 84.4 M | 6.1 M | 2.1 M | 61 M | (89.5 M) | (85 M) |
| MRUS | 6.7 M | 6.7 M | 6.7 M | 6.7 M | (10.7 M) | 34.2 M | 25.3 M | 111.3 M | (6.8 M) | 33.1 M | (34.5 M) | 78.5 M | (93.3 M) | 56.6 M | 89 M | 93.5 M |
| REPL | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | (3 M) | 9.2 M | 34.2 M | 123 M | (76.6 M) | 40.6 M | (72.1 M) | (64.9 M) | (61.6 M) |
| GLUE | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 33.6 M | 308.5 M | (291.2 M) | 72.5 M | 65.2 M | 68.5 M |
| ERAS | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | 36.1 M | 295.2 M | (76.3 M) | (191.1 M) | (172 M) | (163.4 M) |
| LYEL | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | (31.8 M) | 42.4 M | 153.4 M | (170.5 M) | 22.1 M | 19.9 M | 20.9 M |
ProKidney Corp and related stocks such as Relay Therapeutics, Stoke Therapeutics, and Pliant Therapeutics Change In Cash description
My Equities
My Current Equities and Potential Positions
| ProKidney Corp | PROK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | North Carolina; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.92
Check out ProKidney Corp Performance and ProKidney Corp Correlation. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
ProKidney Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.